Why didn t remdesivir enter the clinic in the first place?

Because there is no actual evidence that this drug has a good effect, and how big this drug is has not been proven.

It may be because doctors consider that this drug has not been proven to have good efficacy during the SARS period, so they dare not use it on a large scale easily, and it will take a period of time to study.

Because this is an imported drug, and it is not very sure how effective it is for the new crown pneumonia, it still needs to go through animal experiments before it can enter the clinical stage.

Is remdesivir likely to be widely used in China? Remdesivir is an investigational drug that has only been used in a very small number of patients infected with the novel coronavirus to date, so our efficacy is not well understood and not available to ensure widespread use.

At present, we are in the critical stage of the prevention and control of the novel coronavirus pneumonia epidemic, when will the special drugs for the new coronavirus pneumonia appear? Wang Chen, vice president of the Chinese Academy of Engineering and an expert in respiratory and critical care medicine, said in an interview with Bai Yansong, the host of "News 1+1", last night, that according to the previous results, we have great hopes for remdesivir, and other drugs, including traditional Chinese medicine, we need further clinical observation to determine their efficacy. In particular, we should remind everyone that the effectiveness of individual drugs is not a scientific conclusion, and clinical trials must be conducted.

On February 5, remdesivir, developed by Gilead of the United States, officially launched a clinical trial in Wuhan, and the first batch of cases were enrolled in place, and the first batch of severe patients with pneumonia infected by the new coronavirus will receive medication on February 6.

Recently, remdesivir has been regarded as a "seed player" among the special drugs that are expected to be the first new crown pneumonia. According to reports, on February 2, the clinical trial of remdesivir** new crown pneumonia was approved. Subsequently, it was reported that remdesivir "worked well in the first case of 270 clinical trials, with less than 24 hours from severe disease to recovery".

In this regard, Cao Bin, the person in charge of the phase III clinical trial of remdesivir in China and a professor at China-Japan Friendship Hospital, told the relevant **: "Science takes time. Randomized double-blind clinical studies, who dares to say efficacy without unblinding?

Regarding the latest advances in remdesivir, Gilead said that remdesivir is an investigational drug that has only been used by a very small number of patients infected with the novel coronavirus to date, so we do not have sufficient understanding of its efficacy and are not currently sufficient to ensure that the drug is widely available. While it has not yet been determined whether the drug is safe and effective for COVID-19 infection, given the urgency of the current situation, a number of measures are being taken to speed up production and increase**, including the expansion of a network of external pharmaceutical partners to accelerate the procurement of raw materials, the production of APIs and drug products.

Remdesivir, even after the third phase of the trial, is also a side-rubbing pill, and it is impossible to apply it on a large scale, because the function of traditional Chinese medicine has long surpassed the synthesis of Western medicine, don't hope to lose too much money and lose your wife.

It is uncertain whether the drug has clinical value, as many institutions have not yet published its actual effects.

The drug is still in clinical trials, and it is not clear whether it will be effective against the coronavirus, because the drug has not been approved for clinical use in any country, so it should not be widely used for the time being.

It is difficult to be widely used, because this drug is still in clinical trials, and when it can be used, a vaccine may have been developed, and this drug is more expensive than other drugs because it is an imported drug.

Since the outbreak of the new crown pneumonia epidemic, "remdesivir", a drug originally developed by Gilead in the United States to fight the Ebola virus, has suddenly attracted attention - because it was found to have a certain efficacy against the new crown pneumonia, the drug was once regarded as a "miracle drug" that can ** the new crown pneumonia. After Gilead announced the pricing of remdesivir, many Americans exclaimed: Can't afford it!

According to U.S. reports, according to Gilead's pricing, and considering that remdesivir can shorten the patient's hospital stay and save $10,000 per person in medical expenses, the current pricing is far below the actual value of the drug. Insured U.S. patients pay $520 for one dose of remdesivir, which means they will have to pay $3,120 to complete a five-day, six-dose course. Patients with Medicare will pay $2,340 per course of treatment, with a unit price of $390 per dose.

A doctor interviewed by the Associated Press said that for a drug like remdesivir, which cannot reduce mortality, the price is indeed high. The doctor also pointed out that Gilead used a lot of U.S. taxpayer money in the research and development process, so ** should take over the production of the drug and distribute it to patients for free. A lawyer for a consumer advocacy group in the United States said Gilead used at least $70 million in public funding to develop remdesivir.

At present, clinical trials from China and the United States have found that remdesivir has a relatively limited effect on new crown pneumonia, which can shorten the length of hospital stay of patients by about 30%, but has no obvious effect on reducing mortality. <>

Despite this, the drug is still officially recognized and approved by the United States for its certain efficacy. On Twitter, an overseas social platform, a large number of American netizens and some American politicians also expressed strong dissatisfaction with remdesivir. Senator Bernie Sanders said the "greedy" behavior of a $15 billion company that would price a drug developed a year ago for more than $3,000 must be stopped.

So, for the American people with average economic conditions, many people can't afford this**.

Ordinary people can't afford to pay, because the average person's monthly income is less than 10,000 yuan, and in addition to this drug, they will also need to use other drugs.

For ordinary people, it is really unaffordable, because it is too expensive, and it is actually relatively expensive for some rich people, but they can afford it.

This drug is known as the "miracle drug" for new coronavirus infection, but in some field hospitals in the United States, this drug is expensive. For those patients who are not so wealthy, these ** costs may not be affordable.